---
title: "Health care roundup: Market talk"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295431828.md"
description: "Find insight on Novartis, Sandoz Group, ResMed and more in the latest Market Talks covering health care."
datetime: "2026-08-10T16:41:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295431828.md)
  - [en](https://longbridge.com/en/news/295431828.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295431828.md)
generator: "portal-rs"
---

# Health care roundup: Market talk

Find insight on Novartis, Sandoz Group, ResMed and more in the latest Market Talks covering health care.

### Related Stocks

- [SDZNY.US](https://longbridge.com/en/quote/SDZNY.US.md)
- [RMD.US](https://longbridge.com/en/quote/RMD.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)
- [RMD.AU](https://longbridge.com/en/quote/RMD.AU.md)

## Related News & Research

- [Novartis announces Phase 3 pelacarsen study did not meet primary endpoint](https://longbridge.com/en/news/298086918.md)
- [Bank Vontobel Reaffirms Their Hold Rating on Novartis AG (NOVN)](https://longbridge.com/en/news/298204117.md)
- [Novartis Just Lost a Potential $6 Billion Drug Opportunity](https://longbridge.com/en/news/298222548.md)
- [Novartis’ pelacarsen fails to meet primary endpoint in Lp(a) HORIZON trial](https://longbridge.com/en/news/298200227.md)
- [Novartis Pelacarsen Fails to Cut Cardiovascular Events in Key Phase III Lp(a) Trial](https://longbridge.com/en/news/298080194.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**